Drug intelligence / Profile preview

paclitaxel + tegafur + uracil

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination chemotherapy regimen consisting of paclitaxel and UFT (tegafur/uracil). Paclitaxel is a taxane that stabilizes microtubules and prevents cell division. Tegafur is a prodrug that converts to 5-fluorouracil (5-FU) in the body, while uracil helps maintain higher levels of 5-FU by inhibiting its degradation through competitive inhibition of dihydropyrimidine dehydrogenase (DPD). This combination has been studied in clinical trials for metastatic breast cancer.

Targets

DPYD (Dihydropyrimidine dehydrogenase)TUBB (Tubulin (alpha and beta subunits))TS (Thymidylate synthase)

Beyond the preview

Go deeper on paclitaxel + tegafur + uracil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on paclitaxel + tegafur + uracil.

Explore the full profile